Emergent BioSolutions’ New President and CEO, Bob Kramer, joins Rich Bendis on BioTalk

By | News | No Comments

Bob Kramer joins BioTalk to discuss his history with Emergent, his vision for the company, and Emergent’s commitment to the BioHealth Capital Region.

Mr. Kramer serves as president and CEO and as a member of the Board of Directors. He was appointed as CEO and as director effective April 2019 and has served as president since March 2018. Mr. Kramer also served as chief operating officer from March 2018 to March 2019. Prior to this, Mr. Kramer served as executive vice president and chief financial officer from September 2012. Mr. Kramer first joined Emergent in 1999 as its CFO. From 1999 until his retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining Emergent in 1999, Mr. Kramer held various financial management positions at Pharmacia Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc. Mr. Kramer serves on the board of the U.S. Chamber of Commerce. Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University.

Listen now on iTunes (https://apple.co/2P2fYfO), Google (http://bit.ly/2KKg47H), and TuneIn (http://bit.ly/2LPtYab).

ivWatch Headquarter Operations Opens Doors on Aug. 16 for Ribbon-Cutting

By | News | No Comments

Medical device manufacturer welcomes visitors during Tech Center event

NEWPORT NEWS, Va., August 13, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, will participate in the ribbon-cutting celebration at 10:30 a.m. on August 16, 2019 for the opening of Tech Center Research Park’s Building One. The building, in which ivWatch is an anchor tenant, is the first of 10 buildings planned for the park.

The company designed, assembles, and sells a breakthrough medical device which uses sensor technology to monitor what is happening below the skin and into the tissue during drug/fluid delivery and can detect leakage before the human eye. When the ivWatch system detects a leakage, known as an infiltration, it alerts the medical team to inspect the IV site.

“We have entirely transitioned from being a research and development company to an extensive operation serving health care institutions all over the world,” said Gary Warren, president and CEO of ivWatch. “The strategic build-out in a first-class facility like this provides us with all necessary resources to continue to innovate and make waves in our industry.”

While scouting possible headquarter relocation options, the company required a facility that could adapt to support the year-over-year growth projections of the company and a manufacturing space that would allow the company to build in-house production capabilities.

ivWatch operations are housed within a 25,000 sq. ft. footprint including state-of-the-art manufacturing, R&D and office space, and a large medical setting used to conduct pre- and post-market clinical studies.

Click here to read the entire release.

BioHealth Innovation’s Entrepreneur-In-Residence, Dr. Ethel Rubin, joins Rich Bendis on BioTalk to discuss her career, joining BHI, and her work with the NIH

By | BioTalk, News | No Comments

For the first time, a BioTalk look inside BioHealth Innovation, Inc. (BHI) with Entrepreneur-In-Residence (EIR) Dr. Ethel Rubin

Dr. Ethel Rubin leads a venture team that helps prepare and connect lifescience companies with capital, ensuring strategies that hit valuation inflection points, achieve strategic goals, and prepare for a product launch. She has previously held corporate leadership roles in global clinical strategy and medical affairs at Medtronic, plc, was Chief Scientific Officer of BioFortis, Inc. (acquired by Quintiles-Quest JV) and CSA Medical, Inc., is President of life sciences business development advisory firm Innovative BioStrategies, LLC, and a venture partner at various funds. She has over 25 products in the marketplace garnering 9 figure sales revenue, was instrumental in multiple M&As, partnerships & collaborations, and advises hundreds of CEOs in preparation for seed to series B financing each year. Ethel has held board seats at tech incubators and numerous business and clinical Advisory boards.  Dr. Rubin earned a Ph.D. in Biochemistry and Biophysics from the University of Rochester School of Medicine & Dentistry and a certificate in corporate governance for Board of Directors service from The George Washington University School of Business.

Listen now on iTunes (https://apple.co/318CzZv), Google (http://bit.ly/30WiQfg), and TuneIn (http://bit.ly/2LPtYab).

RoosterBio Raises $15 Million in Initial Series B Round Led by Dynamk Capital

By | News | No Comments

New Funding, Anticipated to Close at $22 Million, to Fuel Growth of its Regenerative Medicine MSC Manufacturing Platform Worldwide, Scale the Organization, and Accelerate R&D Innovation

Frederick, MDAug. 6, 2019 /PRNewswire-PRWeb/ — RoosterBio Inc, disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, today announced it has raised in excess of $15 million in an initial Series B financing round led by Dynamk Capital. Existing and new investors exhibited strong investment interest, leading to an oversubscribed round. The Series B final round is expected to close with additional investors by the end of August, totaling approximately $22 million raised. The investment will be used to expand and scale the RoosterBio team as its customer base continues to grow internationally, while bolstering research and development for their transformative next generation cell and gene therapy solutions. This funding round represents the powerful partnership between a venture team of industry experts specifically targeting creative life science industrials developing technologies and business models that change the paradigm of biopharmaceutical research, development and biomanufacturing.

“It is critical that we empower scientists to get innovative products to the market more efficiently in order to develop life-saving cures,” said Daniella Kranjac, Founding Partner of Dynamk Capital. “RoosterBio’s pioneering biotechnology platform is driving the revolutionary field of regenerative medicine which has the potential to develop therapies for previously untreatable diseases and conditions. We look forward to helping RoosterBio scale their business and make their technology more broadly available.”

Click here to read the entire Press Release.

Precision For Medicine Launches Biospecimen Solutions Offering With Acquisition Of ProMedDx And GLAS

By | News | No Comments

ADDITION OF LEADING SUPPLIERS BOLSTERS PRECISION’S BIOMARKER SERVICE OFFERINGS– BRINGING UNPARALLELED SCIENCE, SCALE AND SERVICE TO THE BIOSPECIMEN INDUSTRY

BETHESDA, Md.Aug. 1, 2019 /PRNewswire/ — Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.

The addition of ProMedDx and GLAS establishes an unrivaled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout the diagnostics industry for its high-quality biofluid specimens; GLAS is a leader in tissue-based samples. With an expanded sourcing network and client base, along with an enhanced global laboratory infrastructure, Precision can effectively leverage its unique insight as a scientific solutions provider to supply clients with hand-selected, fit-for-purposes specimens for R&D, biomarker development, and companion diagnostics.

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Combining two world-class biospecimen organizations, across all specimen types, Precision further enhances its abilities to enable life science innovators with scientifically robust services to accelerate the pace of discovery, development, and commercialization of biomarkers.

Click here to read the entire release.

Regenxbio out-licenses gene therapy vector to Pfizer

By | News | No Comments

REGENXBIO (NASDAQ:RGNX) inks an agreement with Pfizer (NYSE:PFE) granting it a non-exclusive global license, with sublicense rights, to its NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of a rare inherited neurodegenerative movement disorder called Friedreich’s ataxia.

Under the terms of the deal, RGNX will receive an upfront payment, milestones and royalties on net sales. Specific financial terms are not disclosed.

Via Seeking Alpha

Virginia Bio Names John Newby CEO

By | News | No Comments

RICHMOND, Va.–(BUSINESS WIRE)–Virginia Bio, the statewide non-profit trade association for the life science industry, today announces that John L. Newby II is named CEO, effective August 5, 2019.

Newby will be leaving his current role as the Commissioner of the Virginia Department of Veterans Services (VDVS), where he leads an 850-member Agency located across 50 Virginia locations, delivering employment, education, benefits, behavioral health and long term health care services to Virginia’s Reservists, Guardsmen, transitioning service members and 725,000 veterans.

Andrew Krouse, Chairman of the Board Virginia Bio and CEO of the clinical stage pharmaceutical company Cavion, Inc., Charlottesville, VA, said: “We are fortunate to have someone of John Newby’s caliber and leadership experience at the helm of Virginia Bio. We face great opportunity for our members, the industry and the state, in rapidly changing times. Newby is an extraordinarily experienced leader with statewide responsibilities and national vision. He has a heart for service and an extraordinary dedication to Virginia. He has a proven track record of execution. He is passionate about the opportunities in our industry and knows what it takes to turn ideas into reality.”

Prior to leading VDVS Newby practiced corporate, intellectual property and Hatch-Waxman biopharmaceutical law at international law firms in Richmond and Washington DC, and at a multinational company. Newby previously commanded an Air Force special operations unit supporting the U.S. Army’s 3rd and 7th Special Forces Groups (Airborne), and served in Iraq as an aviator aboard the Boeing B-1B Lancer strategic bomber. Newby received his commission and Bachelor of Science degree from the United States Air Force Academy and earned his Juris Doctor from the University of Virginia School of Law.

Click here to read the entire release.

Maryland VC totals ‘rebound’ with $226M raised in Q2

By | News, Uncategorized | No Comments

Venture funding raised by Maryland companies took a big jump in the second quarter of the year, as companies in the state raised a total of $226 million.

That’s a 180% increase over the first quarter total of $80 million, according to data from a PwC/CB Insights MoneyTree report. The number of deals also increased, from 19 in the first quarter to 21.

When it comes to overall totals, it marked a “a significant rebound for the state,”  said Brad Phillips, a director in PwC’s Emerging Company Services practice. It came after totals dipped in Q1 coming off a year in 2018 that saw the highest VC haul since 2001.

It also followed an overall trend that makes judging a single quarter difficult, as Maryland consistently sees up-and-down totals from quarter to quarter in the region.

Phillips also noted that three of the top five deals in the region were for Maryland-based companies, as well as 62% of the funding and more than half the number of deals within the DMV region. Those three biggest deals all came from Gaithersburg-based companies in the form of a $75 million Series B investment in biotech company Viela Bio, a $50 million Series B for on-demand manufacturing marketplace Xometry and a $22 million Series C for biopharmaceutical company Sirnaomics. Overall, the state ranked 12th in the U.S. for number of dollars invested and 11th for number of deals.

Read more via Technical.ly Baltimore.

Illumina Establishes First East Coast Location in University of Maryland BioPark

By | News | No Comments

BALTIMOREJuly 11, 2019 /PRNewswire/ — The University of Maryland (UM) BioPark and Wexford Science & Technology, LLC, today announced Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, as the newest tenant in the UM BioPark’s 801 W. Baltimore St. building. The building is owned by Ventas, Inc., a life sciences real estate investment trust (REIT) and is part of Wexford’s Knowledge Community development at the UM BioPark.

Illumina’s 13,000-square-foot space in the UM BioPark will house its new Illumina Solutions Center facility, providing training lab capabilities and office space for customers and commercial teams. It will be the company’s first commercial location on the East Coast and will host hundreds of employees and customers annually.

“Our team is excited for the opportunity to inhabit the UM BioPark and to build upon our strong working relationship with the University of Maryland School of Medicine’s Institute for Genome Sciences and its Director, Claire Fraser, PhD. We believe this will facilitate collaborative engagement in research activities with our academic partner, University of Maryland, Baltimore (UMB),” shared Mark Van Oene, Senior Vice President and Chief Commercial Officer for Illumina. “We are inspired by all the ways genomics can stimulate economic activity to maximize impact in the region and fuel research with the potential to improve health outcomes for patients.”

Click here to read the entire press release.

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

By | News | No Comments

ROCKVILLE, Md. and SHANGHAIJuly 10, 2019 /PRNewswire/ — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company committed to the discovery and development of first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, announced today that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab. This investigational drug is an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates MacroGenics’ proprietary Fc Optimization technology platform. Enoblituzumab represents one of the most advanced programs in development directed against B7-H3, a target for which no agent is currently approved. I-Mab obtains regional development and commercialization rights in mainland ChinaHong KongMacau and Taiwan.

As part of the collaboration, I-Mab will both lead regional studies in its territories as well as participate in global studies conducted by MacroGenics. MacroGenics intends to initiate a Phase 2 study of enoblituzumab in combination with MGA012 (also known as INCMGA0012), an investigational anti-PD-1 antibody that MacroGenics licensed to Incyte Corporation, in first-line patients with head and neck cancer later this year.

“We are very pleased to be partnering with I-Mab to further accelerate and broaden the development of enoblituzumab and to support our mission of bringing innovative medicines to patients with high unmet medical needs,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. “We believe that I-Mab is an ideal partner given its track record of rapidly progressing innovative immuno-oncology programs and its ability to tap into the growing pharmaceutical market in this region.”

Click here to read the entire release.

Join our Mailing List